Functionality of the B.44 drug programme “Treatment of Patients with Severe Asthma” in 2025 from the perspective of medical centres
Marek Kulus
1
,
Karina Jahnz-Różyk
2
,
Radosław Gawlik
3
,
Maciej Kupczyk
4
,
Łukasz Skolimowski
5
,
Aleksander Junak
5
,
Anna Ben Drissi
5
- Department of Paediatric Pneumonology and Allergology, Medical University of Warsaw, Poland
- Department of Internal Medicine, Pneumonology, Allergology, Clinical Immunology and Rare Diseases, Military Medical Institute – National Research Institute, Warsaw, Poland
- Department of Internal Medicine, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland
- Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Poland
- Polish Society of Allergology, Coalition for Asthma Treatment, Lodz, Poland
Data publikacji online: 2026/03/20
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
